Skip to main content
SpringerLink
Log in

A Review of the Efficacy, Tolerability and Safety of Sertindole in Clinical Trials

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Sertindole is a non-sedating atypical antipsychotic agent with high selectivity for dopaminergic neurons in the mesolimbic system. In pivotal clinical trials, sertindole has demonstrated significantly greater efficacy than placebo against both the positive and negative symptoms of schizophrenia. In addition, sertindole has had at least similar efficacy to haloperidol and risperidone against positive symptoms, and significantly greater efficacy than haloperidol and risperidone against negative symptoms. The incidence of extrapyramidal symptom (EPS)-related adverse events and the rate of medication used to treat EPS in patients receiving clinically effective doses of sertindole in clinical trials were similar to those observed in placebo recipients and significantly less than those in haloperidol recipients. The incidence of QTc interval prolongation of 500 ms or greater with therapeutic dosages of sertindole has also been low. In general, sertindole has been well tolerated in clinical trials. Unlike other antipsychotic agents, sertindole has not been associated with cognitive impairment, and can actually improve cognitive function. Observational studies have shown that the efficacy and tolerability of sertindole observed in the clinical trial situation are emulated in a naturalistic setting. Large cohort analyses (N > 8000) have shown that all-cause and cardiovascular mortality is no greater with sertindole than with risperidone or olanzapine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table II
Fig. 6

Similar content being viewed by others

References

  1. Sanchez C, Arnt J, Dragsted N. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1992; 22: 239–50

    Article  Google Scholar 

  2. Hyttel J, Neilsen JB, Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha one receptors. J Neural Transm 1992; 89: 61–9

    Article  CAS  Google Scholar 

  3. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992; 10: 25–33

    Article  PubMed  CAS  Google Scholar 

  4. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996; 124: 168–75

    Article  Google Scholar 

  5. Kasper S. How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol 1998; 13(Suppl. 3): S71–S7

    Article  PubMed  Google Scholar 

  6. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782–91

    PubMed  CAS  Google Scholar 

  7. Hale A, Azorin J-M, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 2000; 4: 55–62

    Article  CAS  Google Scholar 

  8. Daniel DG, Wozniak PJ, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998; 34: 61–9

    PubMed  CAS  Google Scholar 

  9. Haverkamp W, Eckhardt L, Matz J, et al. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002; 6(Suppl. 1): S11–S20

    Article  CAS  Google Scholar 

  10. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 2002; 6(Suppl. 1): S3–S9

    Article  CAS  Google Scholar 

  11. Branford D, Thompson B, Muldoon C. Mortality in three comparative cohorts of patients who received sertindole, risperidone, and olanzapine: a hospital-based retrospective study. Poster presented at ICPE. Edinburgh, 18–21 August 2002

  12. Wilton LV, EL H, Pickering RM, et al. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol (Oxf) 2001; 15:120–6

    Article  CAS  Google Scholar 

  13. Azorin J-M, Toumi M, Sloth-Nielsen M. Sertindole is well tolerated and demonstrates efficacy advantages over risperidone in the treatment of moderate to severe schizophrenia. Poster presented at ECNP. Barcelona, 5–9 October 2002

  14. Hale A. Sertindole: a clinical efficacy profile. Psychiatry Clin Pract 2002; 6(Suppl. 1): S21–S6

    Article  CAS  Google Scholar 

  15. Lis S, Krieger S, Gallhofer B, et al. Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia: a comparative study. Poster presented at ECNP. Prague, 20–24 September 2003

  16. Steinert T, Hauger B, Eckhardt J, et al. Clinical observations of sertindole in 53 consecutive cases. Psycopharmakotherapie 2003; 10: 62–5

    Google Scholar 

  17. Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998; 13(Suppl. 3): S65–S70

    Article  PubMed  Google Scholar 

  18. Lundbeck. data on file

  19. Serdolect1 (sertindole) monograph. Available at URL http://www.serdolect.com Accessed 13 November 2003

  20. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82

    Article  PubMed  CAS  Google Scholar 

  21. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 62–9

    Article  PubMed  CAS  Google Scholar 

  22. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterisation of the antipsychotic drug sertindole in a rabbit heart model of torsade de points: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002; 300: 64–71

    Article  PubMed  CAS  Google Scholar 

  23. Toumi M, Anquier P, Francois C. The safety and tolerability of sertindole in a patient name use programme. Poster presented at ICPE. Edinburgh, 18–21 August 2002

  24. Peuskens J, Moore N, Azorin J, et al. Sertindole European Safety and Exposure Survey: a retrospective study of 8,608 patients in Europe. Poster presented at ICPE. Edinburgh, 18–21 August 2002

  25. Sturkenboom MCJM, Picelli G, Moore N. Mortality during use of sertindole and other anti-psychotics in the Netherlands and Belgium. Pharmacoepidemiol Drug Safety 2001; 10(Suppl. 1): S116

    Google Scholar 

  26. Kasper S, Quiner S, Pezawas L. A review of the benefit:risk profile of sertindole. Int J Psychiatry Clin Pract 1998; 2(Suppl. 2): S59–S64

    CAS  Google Scholar 

  27. Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in schizophrenia and affective disorders. J Clin Psychiatry 2003; 64: 1122–9

    Article  PubMed  Google Scholar 

  28. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82–91

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The data source for the manuscript was literature retrieval, the Serdolect product monograph, and manuscripts in preparation provided by H. Lundbeck A/S.

Author information

Authors and Affiliations

  1. Psychiatric Center Amsterdam Valeriuskliniek, Valeriusplein 9, 1075 BG, Amsterdam, the Netherlands

    Lowijs Perquin

  2. Department of Psychiatry, Weissenau Research Unit, Ravensburg, Germany

    Tilman Steinert

Authors
  1. Lowijs Perquin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tilman Steinert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perquin, L., Steinert, T. A Review of the Efficacy, Tolerability and Safety of Sertindole in Clinical Trials. CNS Drugs 18 (Suppl 2), 19–30 (2004). https://doi.org/10.2165/00023210-200418002-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418002-00003

Keywords

Search

Navigation